AbbVie IBD data scheduled for UEG Week 2026 highlight long-term treatment outcomes for Skyrizi and Rinvoq, alongside real-world findings in Crohn’s disease. The company announced the 20-abstract program on October 17, 2026, for the congress taking place October 17–20 in Barcelona, Spain.
Key Takeaways
- Long-term analyses cover Skyrizi in ulcerative colitis and Rinvoq in Crohn’s disease.
- Interim UPlift results showed a median 13 days to first clinical response with Rinvoq.
- The program includes investigational treatments and delivery approaches, not new regulatory approvals.
Table of Contents
- AbbVie IBD data focus on sustained treatment outcomes
- Real-world Rinvoq findings add response and care-use measures
- Pipeline presentations extend beyond established treatments
- Conclusion
AbbVie IBD data focus on sustained treatment outcomes
AbbVie’s UEG Week presentation announcement brings together longer-term studies, real-world treatment data and pipeline research in inflammatory bowel disease. The central question is how patients with chronic Crohn’s disease or ulcerative colitis respond beyond the initial treatment period.
In ulcerative colitis, the COMMAND study reported sustained clinical and endoscopic outcomes with Skyrizi, or risankizumab, through up to three years of maintenance treatment. At week 96, as-observed clinical remission rates with the 180 mg dose ranged from 54.0% to 73.1% across groups with and without previous advanced therapy exposure. Endoscopic remission rates ranged from 38.8% to 53.5%.
For Rinvoq, or upadacitinib, U-ENDURE analyses in Crohn’s disease reported clinical remission at week 144 in 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remission was achieved by 47.1% and 64.2%, respectively.
These are as-observed analyses, so the percentages should not be read as remission rates for every patient who originally entered treatment. Clinical and endoscopic remission are also distinct endpoints: the latter assesses disease activity through examination of the bowel.
| Item | Details |
|---|---|
| U-ENDURE long-term extension | Oral presentation scheduled October 19, 2026, 11:30–12:30. |
| AFFIRM induction results | Oral presentation scheduled October 19, 2026, 16:00–17:00. |
| TARGET-CD Phase 2a | Late-breaking presentation scheduled October 19, 2026, 10:00–11:00. |
| Comparative health-care resource use | Oral presentation scheduled October 20, 2026, 14:30–15:30. |
Real-world Rinvoq findings add response and care-use measures
Interim results from UPlift showed that 70.2% of 497 evaluable patients with moderate to severe Crohn’s disease achieved a clinical response within 12 weeks of upadacitinib treatment. The median time to first response was 13 days. A clinical response indicates improvement under the study’s criteria, rather than necessarily remission.
A separate real-world claims analysis involving 514 patients with ulcerative colitis or Crohn’s disease compared switching from a tumor necrosis factor inhibitor to upadacitinib with cycling to another drug in the same inhibitor class. Over 12 months, IBD-related hospitalization rates were 9.5% versus 16.3%, while surgery rates were 6.9% versus 10.6%.
Those observational comparisons describe differences between treatment groups; they do not by themselves establish that switching caused the lower rates.
Pipeline presentations extend beyond established treatments
AbbVie also scheduled additional Phase 3 AFFIRM analyses of subcutaneous risankizumab induction and maintenance in Crohn’s disease. The company said it had submitted an application to the European Medicines Agency on August 27, 2026, seeking approval for subcutaneous induction in adults with moderately to severely active disease.
The program includes Phase 2a TARGET-CD findings for ABBV-466, an investigational dual-targeting therapy. These presentations broaden the research program but should remain distinct from approved indications or confirmed commercial outcomes.
Efficacy findings also need to be considered alongside product safety information. AbbVie’s release identifies infection risks for both medicines and additional restrictions and warnings for Rinvoq in certain higher-risk patient groups.
Conclusion
The next scheduled updates are the October 19 long-term extension, AFFIRM and TARGET-CD presentations, followed by the October 20 health-care resource-use analysis. Those sessions will add detail to a program centered on treatment durability, everyday clinical use and investigational approaches.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
